Effects of a Novel Selective PPARα Modulator, Statin, Sodium-Glucose Cotransporter 2 Inhibitor, and Combinatorial Therapy on the Liver and Vasculature of Medaka Nonalcoholic Steatohepatitis Model

• 資料種別: 博士論文
• タイトル: Effects of a Novel Selective PPARα Modulator, Statin, Sodium-Glucose Cotransporter 2 Inhibitor, and Combinatorial Therapy on the Liver and Vasculature of Medaka Nonalcoholic Steatohepatitis Model
• 著者・編者: Kimura, Atsushi
• 著者標目: Kimura, Atsushi
• 出版年月日等: 2022-03-23
• 出版年（W3CDTF）: 2022-03-23
• 並列タイトル等: 非アルコール性脂肪性肝炎(NASH)メダカモデルの肝臓および血管系に対する新規選択的PPARαモジュレーター、スタチン、ナトリウム-グルコース共輸送体2阻害剤の単剤および併用療法の効果
• 授与機関名: 新潟大学
• 授与年月日: 2022-03-23
• 授与年月日（W3CDTF）: 2022-03-23
• 報告番号: 甲第4974号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 著者別名: 木村, 淳史
• 件名標目: NASH; fli::GFP transgenic medaka; SPPARMα; statin; SGLT2 inhibitor
• 対象利用者: 一般
• 一般注記: Objective: Nonalcoholic steatohepatitis (NASH) is a disease entity with an increasing incidence, with involvement of several metabolic pathways. Various organs, including the liver, kidneys, and the vasculature, are damaged in NASH, indicating the urgent need to develop a standard therapy. Therefore, this study was conducted to investigate the effects of drugs targeting various metabolic pathways and their combinations on a high-fat diet (HFD)-induced NASH medaka model. Methods: To investigate the effects of drugs on vascular structures, the NASH animal model was developed using the fli::GFP transgenic medaka fed with HFD at 20 mg/fish daily. The physiological changes, histological changes in the liver, vascular structures in the fin, and serum biochemical markers were evaluated in a time-dependent manner after treatment with selective peroxisome proliferator-activated receptor α modulator (pemafibrate), statin (pitavastatin), sodium-glucose cotransporter 2 inhibitor (tofogliflozin), and their combinations. Furthermore, to determine the mechanisms underlying the effects, whole transcriptome sequencing was conducted using medaka liver samples. Results: Histological analyses revealed significant suppression of fat accumulation and fibrotic changes in the liver after treatment with drugs and their combinations. The expression levels of steatosis- and fibrosis-related genes were modified by the treatments. Moreover, the HFD induced vascular damages in the fin exhibited milder changes after treatment with the drugs. Conclusion: The effects of treating various metabolic pathways on the medaka body, liver, and vascular structures of the NASH medaka model were evidenced. Moreover, to our knowledge, this study is the first to report whole genome sequence and gene expression evaluation of medaka livers, which could be helpful in clarifying the molecular mechanisms of drugs.; Biochemical and biophysical research communications. 2022, 596, 76-82.; 新大院博(医)第1044号
• 国立国会図書館永続的識別子: info:ndljp/pid/12769041; https://dl.ndl.go.jp/pid/12769041
• コレクション（共通）: 障害者向け資料
• コレクション（障害者向け資料：レベル1）: テキストデータ
• コレクション（個別）: 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• 収集根拠: 博士論文（自動収集）
• 受理日（W3CDTF）: 2023-04-07T23:08:38+09:00
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 掲載誌（URI）: http://hdl.handle.net/10191/0002000830; https://niigata-u.repo.nii.ac.jp/records/2000830
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp